Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Therapy-related acute myeloid leukemia (t-AML), defined as AML arising from prior
cytotoxic, radiation, or immunosuppressive therapy for an unrelated disease, accounts for …

Purpose: To evaluate efficacy and safety of venetoclax+ azacitidine in treatment-naïve
patients with acute myeloid leukemia harboring poor-risk cytogenetics and TP53 mut or …

CPX-351 and venetoclax and azacitidine (ven/aza) are both indicated as initial therapy for
acute myeloid leukemia (AML) in older adults. In the absence of prospective randomized …

Abstract Purpose of Review Treatment of elderly patients with acute myeloid leukemia is a
known challenge for hematologists due to patient diversity, heterogeneous disease biology …

Measurable residual disease (MRD) detected by multiparametric flow cytometry (MFC) is
associated with unfavorable outcome in patients with AML. A simple, broadly applicable …

For decades, intensive chemotherapy (IC) has been considered the best therapeutic option
for treating acute myeloid leukemia (AML), with no curative option available for patients who …

Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk
and/or secondary AML | Blood Advances | American Society of Hematology Skip to Main …

Secondary acute myeloid leukemia includes acute myeloid leukemia that arises either from
a previous myeloid hematologic disease such as myelodysplastic syndrome, chronic …

Simple Summary Assessment of measurable residual disease (MRD) identifies small
numbers of acute myeloid leukemia (AML) cells that may remain after initiating treatment …